Business Description

Roche Holding AG
NAICS : 325412
SIC : 2834
ISIN : CH0012032048
Share Class Description:
RHHVF: Ordinary SharesDescription
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.26 | |||||
Equity-to-Asset | 0.3 | |||||
Debt-to-Equity | 1.19 | |||||
Debt-to-EBITDA | 1.95 | |||||
Interest Coverage | 12.11 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 4.51 | |||||
Beneish M-Score | -2.77 | |||||
WACC vs ROIC |
Growth Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 3.7 | |||||
3-Year EBITDA Growth Rate | -4.7 | |||||
3-Year EPS without NRI Growth Rate | -1 | |||||
3-Year FCF Growth Rate | 1.2 | |||||
3-Year Book Growth Rate | -4.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 6.63 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 4.17 |
Momentum Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 58.81 | |||||
9-Day RSI | 64.2 | |||||
14-Day RSI | 65.2 | |||||
3-1 Month Momentum % | 8.72 | |||||
6-1 Month Momentum % | -6.86 | |||||
12-1 Month Momentum % | 20.15 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.26 | |||||
Quick Ratio | 0.97 | |||||
Cash Ratio | 0.33 | |||||
Days Inventory | 180.6 | |||||
Days Sales Outstanding | 70.09 | |||||
Days Payable | 86.4 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 3.3 | |||||
Dividend Payout Ratio | 0.51 | |||||
3-Year Dividend Growth Rate | 1.8 | |||||
Forward Dividend Yield % | 3.25 | |||||
5-Year Yield-on-Cost % | 3.75 | |||||
3-Year Average Share Buyback Ratio | 2.2 | |||||
Shareholder Yield % | 0.87 |
Profitability Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 73.1 | |||||
Operating Margin % | 24.27 | |||||
Net Margin % | 17.53 | |||||
FCF Margin % | 18.72 | |||||
ROE % | 37.58 | |||||
ROA % | 11.77 | |||||
ROIC % | 16.85 | |||||
3-Year ROIIC % | -44.01 | |||||
ROC (Joel Greenblatt) % | 54.73 | |||||
ROCE % | 22.29 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 22.53 | |||||
Forward PE Ratio | 14.39 | |||||
PE Ratio without NRI | 15.95 | |||||
Shiller PE Ratio | 21.49 | |||||
Price-to-Owner-Earnings | 20.98 | |||||
PEG Ratio | 13.29 | |||||
PS Ratio | 3.95 | |||||
PB Ratio | 8.21 | |||||
Price-to-Tangible-Book | 145.09 | |||||
Price-to-Free-Cash-Flow | 21.12 | |||||
Price-to-Operating-Cash-Flow | 14.87 | |||||
EV-to-EBIT | 18.81 | |||||
EV-to-Forward-EBIT | 12.11 | |||||
EV-to-EBITDA | 15.23 | |||||
EV-to-Forward-EBITDA | 10.66 | |||||
EV-to-Revenue | 4.45 | |||||
EV-to-Forward-Revenue | 4.09 | |||||
EV-to-FCF | 23.78 | |||||
Price-to-GF-Value | 0.88 | |||||
Price-to-Projected-FCF | 1.49 | |||||
Price-to-DCF (Earnings Based) | 0.96 | |||||
Price-to-DCF (FCF Based) | 1.27 | |||||
Price-to-Median-PS-Value | 0.9 | |||||
Price-to-Graham-Number | 10.14 | |||||
Earnings Yield (Greenblatt) % | 5.32 | |||||
FCF Yield % | 4.72 | |||||
Forward Rate of Return (Yacktman) % | 6.81 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:RHHVF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Roche Holding AG Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 68,898.126 | ||
EPS (TTM) ($) | 15.017 | ||
Beta | 0.49 | ||
3-Year Sharpe Ratio | -0.4 | ||
3-Year Sortino Ratio | -0.61 | ||
Volatility % | 26.62 | ||
14-Day RSI | 65.2 | ||
14-Day ATR ($) | 5.655678 | ||
20-Day SMA ($) | 322.834025 | ||
12-1 Month Momentum % | 20.15 | ||
52-Week Range ($) | 233.12 - 340.88 | ||
Shares Outstanding (Mil) | 796.79 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Roche Holding AG Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Roche Holding AG Stock Events
Event | Date | Price ($) | ||
---|---|---|---|---|
No Event Data |
Roche Holding AG Frequently Asked Questions
What is Roche Holding AG(RHHVF)'s stock price today?
The current price of RHHVF is $329.35. The 52 week high of RHHVF is $340.88 and 52 week low is $233.12.
When is next earnings date of Roche Holding AG(RHHVF)?
The next earnings date of Roche Holding AG(RHHVF) is 2025-07-25 Est..
Does Roche Holding AG(RHHVF) pay dividends? If so, how much?
The Dividend Yield %  of Roche Holding AG(RHHVF) is 3.3% (As of Today), Highest Dividend Payout Ratio of Roche Holding AG(RHHVF) was 0.59. The lowest was 0.43. And the median was 0.49. The  Forward Dividend Yield % of Roche Holding AG(RHHVF) is 3.25%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |